Biolegend, 353208, Brilliant Violet 421™ anti-human CD197 (CCR7) Antibody
100tests
Catalog Number: 353208
Send an RFQ.
Category
Loading…
| Verified Reactivity | Human |
|---|---|
| Reported Reactivity | African Green, Baboon, Cynomolgus, Rhesus |
| Antibody Type | Monoclonal |
| Host Species | Mouse |
| Immunogen | CCR7-transfected cells |
| Formulation | Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA). |
| Preparation | The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions. |
| Concentration | Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.) |
| Storage & Handling | The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze. |
| Application | FC - Quality tested |
Unless otherwise stated, the minimum order amount is USD 1,000.
For orders below USD 1,000, an additional handling fee may apply, or we may arrange local delivery / local handover where available.
All quotations are subject to final confirmation, including product availability, lead time, batch information, shipping cost, and applicable export or handling requirements.
For quotation requests, please send an RFQ from website or contact:
Please send inquiries directly to us in the “To” field. Emails sent via BCC, mass mailing, or with unrelated recipients may be automatically filtered and will not be processed.
| Recommended Usage |
|---|
| Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd. Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents. |
| Excitation Laser | Violet Laser (405 nm) |
|---|
| Product Citations | Ols S, et al. 2020. Cell Reports. 30(12):3964-3971. PubMed Im KW, et al. 2023. NPJ Breast Cancer. 9:22. PubMed Preglej T, et al. 2023. Front Immunol. 14:1096096. PubMed Yan F, et al. 2023. Front Cell Infect Microbiol. 13:1152987. PubMed Argüello RJ, et al. 2020. Cell Metab. 32:1063. PubMed Jiang XL, et al. 2021. Nat Commun. 12:897. PubMed Behr FM, et al. 2021. Eur J Immunol. 51:151. PubMed Combes AJ, et al. 2022. Cell. 185:184. PubMed Ning J, et al. 2022. Cancer Immunol Immunother. 71:1863. PubMed Xu Q, et al. 2023. Nat Immunol. 24:186. PubMed Asashima H, et al. 2023. Cell Rep. 42:111895. PubMed Zhong J, et al. 2023. Front Immunol. 13:1081889. PubMed Eslamizar L, et al. 2021. NPJ Vaccines. 6:15. PubMed Karlsson H, et al. 2015. PLoS One. 10: 0144787. PubMed Cassotta A, et al. 2019. Nat Med. 25:1402. PubMed Spandan V Shah et al. 2018. Cell reports. 25(10):2766-2774 . PubMed Mandolesi M, et al. 2021. Cell Reports Medicine. 2(4):100252. PubMed Findlay EG, et al. 2019. Oncoimmunology. 8:1608106. PubMed Ahmed R, et al. 2020. Cell Rep. 33:108501. PubMed Pan YG, et al. 2021. Immunity. 54(6):1245-1256.e5. PubMed Ramaswamy A, et al. 2021. Immunity. 54(5):1083-1095.e7. PubMed Szabo PA, et al. 2021. Immunity. 54(4):797-814.e6. PubMed Wallin J, et al. 2016. Nat Commun. 7:12624. PubMed Geiger R, et al. 2016. Cell. 167:829-842. PubMed van der Ploeg K, et al. 2022. Cell Rep Med. 3:100640. PubMed Richert-Spuhler LE, et al. 2021. Cell Reports Medicine. 2(6):100322. PubMed Thompson EA, et al. 2019. Cell Rep. 28:1127. PubMed Siddiqui I et al. 2019. Immunity. 50(1):195-211 . PubMed Bovay A, et al. 2020. Hum Vaccin Immunother. 16:3103. PubMed Azeem W, et al. 2021. Biomedicines. 9: . PubMed Yu C, et al. 2021. Med (N Y). 2:755. PubMed Pais Ferreira D, et al. 2020. Immunity. 53(5):985-1000.e11. PubMed Grifoni A, et al. 2020. Cell. 181(7):1489-1501.e15.. PubMed Barcelo H, et al. 2018. Curr Protoc Cytom. 84:e35. PubMed Cassotta A, et al. 2020. J Exp Med. 217:00:00. PubMed Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed Bziat V, et al. 2021. Cell. . PubMed Port JR, et al. 2020. J Virol. 94:. PubMed Lozano-Rodríguez R, et al. 2022. Cell Rep. 38:110235. PubMed Waddington KE, et al. 2020. Front Immunol. 1.51875. PubMed Halkias J, et al. 2019. J Clin Invest. 130:3562. PubMed Marcandalli J et al. 2019. Cell. 176(6):1420-1431 . PubMed Dai Z, et al. 2022. Signal Transduct Target Ther. 7:85. PubMed Omer B, et al. 2022. Cancer Immunol Res. 10:512. PubMed Neumann B, et al. 2015. J Leukoc Biol. 97:19. PubMed Georg P, et al. 2022. Cell. 185:493. PubMed Rosato PC, et al. 2019. Nat Commun. 10:567. PubMed Sparber F, et al. 2019. Cell Host Microbe. 25:389. PubMed Azeem W, et al. 2020. Front Immunol. 11:438. PubMed Thyagarajan B, et al. 2018. J Immunol Methods. 463:61. PubMed Nobs SP, et al. 2017. J Exp Med. 214:3015. PubMed Abd Hamid M et al. 2019. Cancer Immunol Res. 7(8):1293-1306 . PubMed Gustafson CE, et al. 2020. JCI Insight. 5:. PubMed Benner M, et al. 2020. Cell Rep. 32:108204. PubMed Darrah PA, et al. 2019. NPJ Vaccines. 4:21. PubMed Fu J, et al. 2021. J Clin Invest. 131:. PubMed Grutza R, et al. 2020. J Immunol. 204:2910. PubMed Cassotta A, et al. 2020. Eur J Immunol. . PubMed Gerna G, et al. 2015. J Gen Virol. 96:360. PubMed Vadaq N, et al. 2022. iScience. 25:105089. PubMed |
|---|
| RRID | AB_10915137 (BioLegend Cat. No. 353207) AB_11203894 (BioLegend Cat. No. 353208) |
|---|
| Structure | Chemokine receptor, G protein-coupled receptors (GPCR), seven transmembrane receptor. |
|---|
| Distribution | T cells, B cells, NK, dendritic cells. |
|---|
| Function | The chemokine receptor CCR7 plays a pivotal role in the homing of naïve T cells and regulatory T cells to secondary lymphoid organs, and the migration of dendritic cells into afferent lymphatic vessels. |
|---|
| Ligand/Receptor | CCL19 and CCL21. |
|---|
| Cell Type | B cells, Dendritic cells, NK cells, T cells |
|---|
| Biology Area | Immunology |
|---|
| Molecular Family | CD Molecules, Cytokine/Chemokine Receptors, GPCR |
|---|
| Antigen References | 1. Yanagihara S, et al. 1998. J. Immunol. 161:3096. 2. Charo IF, et al. 2006. N. Engl. J. Med. 354:610. 3. Reif K, et al. 2002. Nature 416:94. 4. Nakata B, et al. 2008. Oncology 74:69. 5. Brodie T. et al. 2013. Cytometry A. 6: 530-2. PubMed 6. Graves A.J. et al. 2014. Cytometry A. 7: 576–9 PubMed 7. Moncunill G. et al. 2014. Cytometry A. 12: 995-8 PubMed |
|---|
| Gene ID | 1236 |
|---|
| UniProt | View information about CD197 on UniProt.org |
|---|
| Clone | G043H7 |
|---|
| Regulatory Status | RUO |
|---|
| Other Names | BLR2, CDw197, EBI1, CMKBR7 |
|---|
| Isotype | Mouse IgG2a, κ |
|---|
